MediWound (MDWD) CMO details options and RSU awards in Form 3 filing

Rhea-AI Filing Summary

MediWound Ltd.’s Chief Medical Officer, Ety Klinger, filed an initial Form 3 showing equity holdings in ordinary shares, stock options, and restricted share units. The filing lists multiple option grants to buy ordinary shares, including 3,571 underlying shares at an exercise price of 36.0500 that expire on December 31, 2028, and 5,491 underlying shares at 12.2500 that expire on April 23, 2030, along with several later-dated grants through March 4, 2036.

Footnotes describe RSU awards granted on February 15, 2023, February 26, 2024, February 11, 2025, and March 4, 2026, each vesting 25% on the first anniversary of grant and 6.25% quarterly over the following three years. The filing also records direct holdings of ordinary shares in several line items.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Klinger Ety

(Last) (First) (Middle)

C/O MEDIWOUND LTD.

42 HAYARKON STREET

(Street)

YAVNE 8122745

(City) (State) (Zip)

ISRAEL

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
MediWound Ltd. [ MDWD ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary shares	1,743	D
Ordinary shares(1)	1,500	D
Ordinary shares(2)	2,828	D
Ordinary shares(3)	1,750	D
Ordinary shares(4)	1,800	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy ordinary shares)	12/31/2022	12/31/2028	Ordinary shares	3,571	$36.05	D
Stock Option (right to buy ordinary shares)	04/23/2024	04/23/2030	Ordinary shares	5,491	$12.25	D
Stock Option (right to buy ordinary shares)	03/04/2025	03/04/2031	Ordinary shares	3,323	$37.52	D
Stock Option (right to buy ordinary shares)	(5)	05/16/2032	Ordinary shares	11,076	$14.42	D
Stock Option (right to buy ordinary shares)	(6)	02/15/2033	Ordinary shares	9,300	$13.32	D
Stock Option (right to buy ordinary shares)	(7)	02/26/2034	Ordinary shares	22,626	$12.729	D
Stock Option (right to buy ordinary shares)	(8)	02/11/2035	Ordinary shares	14,000	$18.54	D
Stock Option (right to buy ordinary shares)	(9)	03/04/2036	Ordinary shares	15,000	$17.6	D

Explanation of Responses:

1. The ordinary shares reported in this row consist of shares underlying restricted share units ("RSUs") that were granted to the Reporting Person on February 15, 2023 and vest in accordance with the following schedule: 25% of the RSUs vested upon the one-year anniversary of the grant date, and an additional 6.25% of the RSUs vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.

2. The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on February 26, 2024 and vest in accordance with the following schedule: 25% of the RSUs vested upon the one-year anniversary of the grant date, and an additional 6.25% of the RSUs vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.

3. The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on February 11, 2025 and vest in accordance with the following schedule: 25% of the RSUs vested upon the one-year anniversary of the grant date, and an additional 6.25% of the RSUs vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.

4. The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on March 4, 2026 and vest in accordance with the following schedule: 25% of the RSUs vested upon the one-year anniversary of the grant date, and an additional 6.25% of the RSUs vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.

5. The options reported in this row were granted to the Reporting Person on May 16, 2022 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.

6. The options reported in this row were granted to the Reporting Person on February 15, 2023 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.

7. The options reported in this row were granted to the Reporting Person on February 26, 2024 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.

8. The options reported in this row were granted to the Reporting Person on February 11, 2025 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.

9. The options reported in this row were granted to the Reporting Person on March 4, 2026 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.

	/s/ Yaron Meyer, attorney-in-fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does MediWound (MDWD) Chief Medical Officer Ety Klinger report on this Form 3?

Ety Klinger reports her initial ownership in MediWound equity, including ordinary shares, stock options, and restricted share units. The form details several option grants with specified exercise prices and expiration dates, plus RSUs with multi-year vesting schedules, giving a structured view of her compensation-linked holdings.

What stock options does Ety Klinger hold in MediWound (MDWD)?

The Form 3 lists several stock option grants to buy MediWound ordinary shares at fixed exercise prices. Examples include options over 3,571 underlying shares at 36.0500 expiring December 31, 2028, and 5,491 underlying shares at 12.2500 expiring April 23, 2030, plus additional grants extending to 2036.

How do Ety Klinger’s MediWound (MDWD) RSU awards vest?

The RSUs generally vest 25% on the first anniversary of the grant date, then 6.25% each quarter over the following three years. This applies to RSUs granted on February 15, 2023, February 26, 2024, February 11, 2025, and March 4, 2026, creating a four-year vesting timeline.

Are there any buy or sell transactions in this MediWound (MDWD) Form 3?

No buy or sell transactions are reported. The Form 3 functions as an initial statement of beneficial ownership, listing existing holdings in stock options, RSUs, and ordinary shares. The transaction summary shows no purchases, sales, exercises, gifts, or tax-withholding events recorded in this filing.

What ordinary share holdings does Ety Klinger report in MediWound (MDWD)?

The filing includes several lines of direct ordinary share holdings, such as 1,743 shares and other amounts, all marked as directly owned. Some ordinary share rows represent shares underlying RSUs described in the footnotes, which vest over four years from their respective grant dates.

What are the expiration dates of Ety Klinger’s MediWound (MDWD) options?

The options expire on various future dates tied to each grant, including December 31, 2028, April 23, 2030, March 4, 2031, May 16, 2032, February 15, 2033, February 26, 2034, February 11, 2035, and March 4, 2036.